Cardiac characterization of 16 patients with large NF1 gene deletions

Clinical Genetics

Volumn 84, Issue 4, 2013, Pages 344-349

  Nguyen, R ^a,b   Mir, Ts ^c   Kluwe, L ^a   Jett, K ^d   Kentsch, M ^e   Mueller, G ^c   Kehrer Sawatzki, H ^f   Friedman, Jm ^d   Mautner, V F ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c Department of Pediatric Cardiology ^*  (Germany)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e Hospital Itzehoe   (Germany)

^f UNIVERSITY OF ULM   (Germany)

Author keywords

Cardiovascular disease; Congenital heart disease; Echocardiography; Neurofibromatosis type 1; NF1 microdeletion

Indexed keywords

ADOLESCENT; ADULT; AORTA STENOSIS; AORTA VALVE REGURGITATION; ARTICLE; CARDIOVASCULAR MALFORMATION; CHILD; CLINICAL ARTICLE; CONGENITAL HEART MALFORMATION; CONTROLLED STUDY; ECCENTRIC MUSCLE CONTRACTION; ECHOCARDIOGRAPHY; FEMALE; GENE; GENE DELETION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE WALL; HEART TUMOR; HEART VENTRICLE SEPTUM DEFECT; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MALE; MITRAL VALVE REGURGITATION; NEUROFIBROMATOSIS; NF1 GENE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD;

CARDIOVASCULAR DISEASE; CONGENITAL HEART DISEASE; ECHOCARDIOGRAPHY; NEUROFIBROMATOSIS TYPE 1; NF1 MICRODELETION;

ADOLESCENT; ADULT; CHILD; ECHOCARDIOGRAPHY; FEMALE; GENE DELETION; GENES, NEUROFIBROMATOSIS 1; HEART DEFECTS, CONGENITAL; HUMANS; MALE; NEUROFIBROMATOSIS 1; YOUNG ADULT;

EID: 84883775895     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/cge.12072     Document Type: Article

References (29)

1. Friedman JM, Gutmann DH, MacCollin M, Riccardi VM. Neurofibromatosis: phenotype, natural history, and pathogenesis, 3 edn. Baltimore, MD: Johns Hopkins University Press, 1999.
2. Kluwe L, Siebert R, Gesk S et al. Screening 500 unselected neurofibromatosis 1 patients for deletions of the NF1 gene. Hum Mutat 2004: 23: 111-116.
3. Bengesser K, Cooper DN, Steinmann K et al. A novel third type of recurrent NF1 microdeletion mediated by nonallelic homologous recombination between LRRC37B-containing low-copy repeats in 17q11.2. Hum Mutat 2010: 31: 742-751.
4. Tonsgard JH, Yelavarthi KK, Cushner S, Short MP, Lindgren V. Do NF1 gene deletions result in a characteristic phenotype? Am J Med Genet 1997: 73: 80-86.
5. Mautner VF, Kluwe L, Friedrich RE et al. Clinical characterisation of 29 neurofibromatosis type-1 patients with molecularly ascertained 1.4Mb type-1 NF1 deletions. J Med Genet 2010: 47: 623-630.
6. Pasmant E, Sabbagh A, Spurlock G et al. NF1 microdeletions in neurofibromatosis type 1: from genotype to phenotype. Hum Mutat 2010: 31: E1506-E1518.
7. Brannan CI, Perkins AS, Vogel KS et al. Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues. Genes Dev 1994: 8: 1019-1029.
8. Gitler AD, Zhu Y, Ismat FA et al. Nf1 has an essential role in endothelial cells. Nat Genet 2003: 33: 75-79.
9. Venturin M, Bentivegna A, Moroni R, Larizza L, Riva P. Evidence by expression analysis of candidate genes for congenital heart defects in the NF1 microdeletion interval. Ann Hum Genet 2005: 69: 508-516.
10. Friedman JM, Arbiser J, Epstein JA et al. Cardiovascular disease in neurofibromatosis 1: report of the NF1 Cardiovascular Task Force. Genet Med 2002: 4: 105-111.
11. Lin AE, Birch PH, Korf BR et al. Cardiovascular malformations and other cardiovascular abnormalities in neurofibromatosis 1. Am J Med Genet 2000: 95: 108-117.
12. Tedesco MA, Di Salvo G, Natale F et al. The heart in neurofibromatosis type 1: an echocardiographic study. Am Heart J 2002: 143: 883-888.
13. Venturin M, Guarnieri P, Natacci F et al. Mental retardation and cardiovascular malformations in NF1 microdeleted patients point to candidate genes in 17q11.2. J Med Genet 2004: 41: 35-41.
14. Dorschner MO, Sybert VP, Weaver M, Pletcher BA, Stephens K. NF1 microdeletion breakpoints are clustered at flanking repetitive sequences. Hum Mol Genet 2000: 9: 35-46.
15. Riva P, Corrado L, Natacci F et al. NF1 microdeletion syndrome: refined FISH characterization of sporadic and familial deletions with locus-specific probes. Am J Hum Genet 2000: 6: 100-109.
16. Stumpf DA, Alksne JF, Annegers JF. Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Arch Neurol 1988: 45: 575-578.
17. Roehl AC, Vogt J, Mussotter T et al. Intrachromosomal mitotic nonallelic homologous recombination is the major molecular mechanism underlying type-2 NF1 deletions. Hum Mutat 2010: 31: 1163-1173.
18. Botto LD, Correa A, Erickson JD. Racial and temporal variations in the prevalence of heart defects. Pediatrics 2001: 107: E32.
19. Marelli AJ, Mackie AS, Ionescu-Ittu R, Rahme E, Pilote L. Congenital heart disease in the general population: changing prevalence and age distribution. Circulation 2007: 115: 163-172.
20. Warnes CA, Liberthson R, Danielson GK et al. Task force 1: the changing profile of congenital heart disease in adult life. J Am Coll Cardiol 2001: 37: 1170-1175.
21. Van de Veire NR, De Backer J, Ascoop AK, Middernacht B, Velghe A, Sutter JD. Echocardiographically estimated left ventricular end-diastolic and right ventricular systolic pressure in normotensive healthy individuals. Int J Cardiovasc Imaging 2006: 22: 633-641.
22. Helmcke F, Nanda NC, Hsiung MC. Color Doppler assessment of mitral regurgitation with orthogonal planes. Circulation 1987: 75: 175-183.
23. Singh JP, Evans JC, Levy D et al. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). Am J Cardiol 1999: 83: 897-902.
24. Frankiewicz L. Rare case of v. Recklinghausen disease with a tumor in the left atrium. Pol Tyg Lek 1973: 28: 411-412.
25. McAllister HA, Fenoglio JJ. Tumors of the cardiovascular system. In: Atlas of tumor pathology, second series. Fascicle 15. Washington, DC: Armed Forces Institute of Pathology, 1987: 70-71.
26. Fischberg C, Cotting J, Hack I, Laurini RN, Payot M. Double compression oesotracheale fatale vasculaire et neurofibromateuse. Arch Pediatr 1996: 3: 1252-1257.
27. Lakkis MM, Epstein JA. Neurofibromin modulation of ras activity is required for normal endocardial-mesenchymal transformation in the developing heart. Development 1998: 125: 4359-4367.
28. Lasater EA, Li F, Bessler WK et al. Genetic and cellular evidence of vascular inflammation in neurofibromin-deficient mice and humans. J Clin Invest 2010: 120: 859-870.
29. Bausch B, Borozdin W, Mautner VF et al. Germline NF1 mutational spectra and loss-of-heterozygosity analyses in patients with pheochromocytoma and neurofibromatosis type 1. J Clin Endocrinol Metab 2007: 92: 2784-2792.